MA-ABIOMED
10.1.2022 14:04:04 CET | Business Wire | Press release
Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device Exemption (IDE) to Impella BTR (Bridge-to-Recovery). In Asia, Impella 5.5 with SmartAssist has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Hong Kong’s Medical Device Division (MDD).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005312/en/
Impella 5.5 with SmartAssist is a game-changing technology for patients in Japan and Hong Kong. It is a minimally invasive, forward flow, fully unloading heart pump designed by and for heart surgeons with direct or axillary insertion. It received FDA post-market approval (PMA) two years ago. Since then, it has been used to treat more than 4,000 US patients for indications that include AMI cardiogenic shock, cardiomyopathy and post-cardiotomy cardiogenic shock. Historically, the cardiogenic shock survival rate has been approximately 50%. Impella 5.5 with SmartAssist patients have a 74% survival to explant, with 59% of surviving patients achieving native heart recovery.
In Japan, Impella 5.5 with SmartAssist is now indicated for use in the treatment of drug-resistant acute heart failure attributable to causes such as cardiogenic shock. The first Impella 5.5 with SmartAssist patient in Japan is expected to be treated in the coming months.
“The Japanese market is ideal for Impella 5.5 with SmartAssist because the technology provides minimally invasive, longer-term unloading support, enabling native heart recovery in a country that is more resistant to invasive sternotomies and heart transplants,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer.
In the United States, the FDA has approved the Impella BTR early feasibility IDE study, clearing the way for the first patient in the world to be treated with Impella BTR. Impella BTR is a percutaneous heart pump, with greater than six liters of blood flow per minute. It is designed to be much less invasive than current LVADs.
The vision of the Impella BTR development program is to provide a patient with home discharge and up to one year of full hemodynamic support. In the early feasibility study, ten patients will be enrolled at up to five hospitals and supported by Impella BTR for up to 28 days. The first Impella BTR patient is expected to be treated in March or April this year.
“The FDA’s approval is a first step toward making this longer-term minimally invasive forward flow smart heart pump a reality for patients with chronic heart failure,” said Minogue.
Impella BTR is an investigational device, limited by federal law to investigational use only.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are US FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are US FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella BTR® is an investigational device, limited by federal law to investigational use only.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com .
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005312/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES to Supply Finnair with Ground-like Connectivity Experience in the Skies2.11.2026 08:00:00 CET | Press release
Multi-orbit inflight connectivity service will deliver faster, more reliable onboard internet experience to 18 Embraer aircraft SES today announced a new agreement with Finnair, Finland's flagship airline, to equip 18 E195-E2s with multi-orbit in-flight connectivity, enabling Finnair’s customers to enjoy fast, reliable internet access throughout their journey. Under the agreement, the Embraer E2 aircraft, which will be line-fitted at Embraer, will be equipped with SES’s electronically steered array antenna (ESA) offering reliable connectivity to the SES multi-orbit network, combining SES’s geostationary (GEO) satellite services with low-earth orbit (LEO) capacity from its partner Eutelsat. The first connected aircraft is expected to enter service in 2027. “Inflight Wi-Fi is a core part of the travel experience,” said Blane Boynton, Senior Vice President Aviation at SES. “SES’s multi-orbit network delivers the reliability, performance and flexibility airlines need today while providing
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 08:00:00 CET | Press release
Physician-investor and co-builder of Sofinnova's AI platform Sofia joins the partnership, underscoring the firm’s growing interest in healthtech and techbio Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprie
Speech Processing Solutions Launches Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct with Real-Time Speech Recognition Directly at Cursor2.11.2026 08:00:00 CET | Press release
Built for professionals who rely on accurate dictation, both solutions combine specialist speech recognition with familiar voice commands allowing users to see recognized text appear directly at the cursor as they speak, while keeping users in control. Speech Processing Solutions (SPS), the global leader in professional dictation and transcription solutions sold under the Philips brand, today announced the launch of Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct. The two solutions allow legal and other professionals to dictate into supported desktop applications, with recognized text appearing as they speak. They are designed both for organizations adopting professional speech recognition for the first time and for customers moving from established or end-of-life speech recognition solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029365830/en/ Philips SpeechLive Legal Direct – legal sp
Thales Selected to Deliver Next-Generation Mine-Hunting Capability for the U.S. Navy2.11.2026 07:00:00 CET | Press release
Thales’ subsidiary Advanced Acoustic Concepts (AAC) won a $53.9 million U.S. Navy contract for two Remote Mine Hunting (RMH) modules and engineering support, with options increasing the potential value to $196.2 million for additional modules. The RMH solution enhances unmanned Mine Countermeasures (MCM) by enabling remote detection and classification and supporting rapid threat engagement, while reducing risk to sailors and platforms. The contract reinforces Thales’ position in MCM and undersea warfare, leveraging international expertise and American innovation to rapidly deliver critical capabilities that enhance U.S. Navy operational readiness and sailor safety in contested maritime environments. Thales’ subsidiary Advanced Acoustic Concepts (AAC), a U.S.-based provider of undersea warfare solutions, was awarded a $53.9 million U.S. Navy contract to produce and deliver two integrated Remote Mine Hunting (RMH) modules and accompanying engineering support. The award includes options f
Uptime Institute and Indonesia Ministry of Communication and Digital Affairs (KOMDIGI) Sign Letter of Intent (LOI) to Support Data Center Policy, Governance, and Industry Development2.11.2026 06:04:00 CET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, and the Ministry of Communication and Digital Affairs (Komdigi) today announced the signing of a Letter of Intent (LOI) to explore collaboration aimed at strengthening Indonesia's data center ecosystem through policy development, governance frameworks, operational excellence, security, sustainability, and workforce capability development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101628182/en/ Uptime Institute and KOMDIGI sign LOI. The Letter of Intent reflects a shared interest in exploring international best practices that may support the development of reliable, secure, efficient, and sustainable digital infrastructure aligned with Indonesia's national priorities and regulatory framework. The LOI was signed by Mustapha Louni, Chief Business Officer, Uptime Institute, and Wayan Toni Supriyanto, Director General of Digital Infrastructure, Indonesia's Min
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom